Physician profile
Mark M Connolly
NPI 1033162839
$1,732.41
in general payments reported to CMS, 2019-2025
13 companies · $218 in 2025
The $218 reported for 2025 was less than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,010 · 2020: $17.76 · 2021: $122 · 2022: $46.44 · 2023: $261 · 2024: $57.27 · 2025: $218.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $416 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $416.20 |
| Education | $119.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $1,083.13 | 2019-2023 | Da Vinci Surgical System |
| Davol INC. | $168.32 | 2022-2025 | Arista |
| Pfizer INC. | $145.87 | 2019-2024 | |
| Puma Biotechnology, INC. | $76.00 | 2023 | |
| Boston Scientific Corporation | $66.30 | 2023 | |
| Ethicon US, LLC | $64.38 | 2025 | Prolene, Vicryl |
| Lemaitre Vascular, INC. | $23.70 | 2023 | Artegraft Vascular Graft |
| Genentech USA, INC. | $19.58 | 2019 | |
| Myriad Genetic Laboratories, INC. | $18.14 | 2021 | |
| Kerecis Limited | $17.94 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Misonix INC | $17.76 | 2020 | |
| Elucent Medical | $17.28 | 2024 | |
| Integra Lifesciences Corporation | $14.01 | 2025 | Integra, Integra Dermal Regeneration Template, Primatrix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Connolly listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.